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Abstract
Background: Neglected tropical diseases are widespread, particularly in sub-Saharan Africa, affecting over 2 billion
individuals. Control of these diseases has gathered pace in recent years, with increased levels of funding from a
number of governmental or non-governmental donors. Focus has currently been on five major ‘tool-ready’
neglected tropical diseases (lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transmitted helminthiasis and
trachoma), using a package of integrated drug delivery according to the World Health Organization guidelines for
preventive chemotherapy.
Discussion: Success in controlling these neglected tropical diseases has been achieved in a number of countries in
recent history. Experience from these successes suggests that long-term sustainable control of these diseases
requires: (1) a long-term commitment from a wider range of donors and from governments of endemic countries;
(2) close partnerships of donors, World Health Organization, pharmaceutical industries, governments of endemic
countries, communities, and non-governmental developmental organisations; (3) concerted action from more
donor countries to provide the necessary funds, and from the endemic countries to work together to prevent
cross-border disease transmission; (4) comprehensive control measures for certain diseases; and (5) strengthened
primary healthcare systems as platforms for the national control programmes and capacity building through
implementation of the programmes.
Conclusions: The current level of funding for the control of neglected tropical diseases has never been seen
before, but it is still not enough to scale up to the 2 billion people in all endemic countries. While more donors
are sought, the stakeholders must work in a coordinated and harmonised way to identify the priority areas and the
best delivery approaches to use the current funds to the maximum effect. Case management and other necessary
control measures should be supported through the current major funding streams in order to achieve the
objectives of the control of these diseases. For a long-term and sustainable effort, control of neglected tropical
diseases should also be integrated into national primary healthcare systems.
Background
A group of chronic and debilitating conditions, caused by
parasitic, bacterial, and viral infections, is defined as the
neglected tropical diseases (NTDs) [1,2]. These NTDs are
the most prevalent diseases in the poorest populations in
the world, putting an estimated 2.7 billion people at risk
[3]. They cause blindness (for example, onchocerciasis
and trachoma) [4-7], disfigurement (for example, lym-
phatic filariasis, leishmaniasis, leprosy, and Buruli ulcer)
[8-12], and are often life threatening at a later stage of
the disease (for example, African trypanosomiasis,
Chagas disease, dengue fever, and schistosomiasis)
[13-17]. They are also related to various clinical compli-
cations, such as anaemia and other forms of malnutrition
(for example, hookworm infections, schistosomiasis,
ascariasis, and trichuriasis) [18-23]. In terms of disability-
adjusted life years (DALYs), NTDs as a whole are among
the top 10 leading causes of years of healthy life lost to
long-term disability and premature death worldwide
[1,3]. Sub-Saharan Africa bears the biggest burden of
many of these NTDs, and the numbers of people afflicted
by each of several of these diseases are simply striking
[24], representing up to over 90% of the world’sb u r d e n
for some of these diseases. Moreover, these NTDs geo-
graphically overlap [1], and a significant proportion of
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these NTDs [2,25,26]. These NTDs have severe socioeco-
nomic consequences as they cause long-term illness, dis-
figurement, social stigma and marginalisation, and
decreased productivity [27,28]. Therefore, successful con-
trol of NTDs will have a wide range of health and socioe-
conomic benefits to the poorest populations. The control
of NTDs has now gained momentum in recent years
with growing interest from the international community
and funding from governmental or non-governmental
donors, however more donors are needed to provide the
funds to bridge the funding gap; the existing donors need
to rethink their funding policy to include other necessary
control measures for certain diseases in order to achieve
the objectives, and the endemic countries need to com-
mit themselves to the NTD control effort. This paper
reviews experiences in the success of controlling these
NTDs from recent history, and highlights the important
aspects in the control of these NTDs in order to achieve
a long-term sustainable effect.
Discussion
Current situation in controlling the five major NTDs
Control of the NTDs currently focuses on five major
‘tool-ready’ NTDs, lymphatic filariasis, onchocerciasis,
schistosomiasis, soil-transmitted helminthiasis (hook-
worm infections, ascariasis, and trichuriasis) and tra-
choma in an integrated control programme [29]. This is
because the drugs needed for these five NTDs are robust,
safe, low cost and available by donation from pharmaceu-
tical companies or by purchasing at relatively low costs.
The current control strategy is mass drug administration
(MDA) using the available drugs in a coordinated
approach according to World Health Organization
(WHO) guidelines on preventive chemotherapy [30].
This drug-based intervention delivers available drugs
either alone or in combination to prevent morbidity
caused by these NTDs, or in some cases to eliminate the
diseases. To date, with the funds committed to deliver
the available tools to the poorest people in need from
external donors, a number of countries, for example,
Bangladesh, Burkina Faso, Cameroon, Democratic
Republic of Congo, Burundi, Ghana, Haiti, Mali, Nepal,
Niger, Rwanda, Sierra Leone, Southern Sudan, Tanzania,
Togo, and Uganda, have been able to implement inte-
grated national NTD control programmes. Although the
current strategy emphasises integrated control by preven-
tive chemotherapy, control of each of these five major
NTDs has its own endpoint targets and its own compre-
hensive measures to achieve these targets (Table 1).
Onchocerciasis
Onchocerciasis, or river blindness, is the second highest
infectious cause of blindness in the world, and is now
mainly distributed in 19 African countries, some foci in
Yemen and parts of the Americas. There are 37 million
people with onchocerciasis and 99% of the cases are in
Africa, with more than 102 million people at risk of the
disease in Africa alone [31]. The control strategy is
through mass administration of ivermectin (Mectizan)
donated by Merck & Co., Inc. through its Mectizan
Donation Program http://www.mectizan.org.
In the Americas, the Onchocerciasis Elimination Pro-
gram for the Americas (OEPA) was launched in 1992 to
act as a technical and coordinating body for a multina-
tional, multiagency coalition that facilitated the estab-
lishment of programmes for the semiannual mass
administration of ivermectin in the six countries with
onchocerciasis [32]. Significant progress has already
been made in all six countries, with no new cases of
onchocercal blindness being reported in the region, and
it is anticipated that onchocerciasis could be eliminated
from most of the remaining foci in the Americas by
2012 [32].
In Africa, the most successful control programme has
been the Onchocerciais Control Program (OCP) which
virtually eliminated river blindness from 11 countries
first by vector control through spraying insecticides and
subsequently through delivery of ivermectin [33]. In
1995, onchocerciasis control was expanded to include
areas outside the original OCP zone with a second pro-
gramme, the African Program of Onchocerciasis Control
(APOC). It adopted a strategy of community-directed
treatment with ivermectin (CDTI) annually [34], deliver-
ing over 50 million treatments per year for onchocercia-
sis in 19 participating countries [31]. Through this
strategy, the prevalence of onchocerciasis in these coun-
tries has been reduced from a precontrol level of 46.5%
in 1995 to 28.5% in 2008 [31]. In some countries, for
example, Senegal and Mali, longitudinal studies in three
foci showed that after 15-17 years of annual or biannual
CDTI, prevalence of onchocerciasis was reduced to
< 1% [35]. This has ignited a hope of eliminating oncho-
cerciasis from Africa.
Lymphatic filariasis
Lymphatic filariasis (LF), or elephantiasis, is widely dis-
tributed throughout the tropical and subtropical areas
of Asia, Africa, the Western Pacific and some parts of
the Americas [36,37]. Globally there are 120 million
people infected with the parasite, causing tremendous
morbidity, with 1.3 billion people at the risk of infection
around the world [3,36]. Successful control of the dis-
ease is exemplified by elimination of LF in China
[38,39] and South Korea [40,41]. In China, the pro-
gramme started in the 1950 s, with a sustained govern-
ment commitment to the elimination of lymphatic
filariasis. Interventions included mass distribution of a
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DEC-fortified salt accompanied by intensive surveillance
to monitor the prevalence of infection. Building on the
successful experience and taking advantage of the avail-
able drug albendazole (donated by GlaxoSmithKline for
areas coendemic with onchocerciasis), the Global Pro-
gram to Eliminate Lymphatic Filariasis (GPELF) was
established in 1997 to elimina t et h ed i s e a s ea sap u b l i c
health problem worldwide by the year 2020. The strat-
egy used is annual MDA with albendazole and DEC or
albendazole and ivermectin to over 80% of the entire
population at the risk of infection. Since 2000, GPELF
has delivered MDA to around 700 million people
worldwide, averting 32 million DALYs and an estimated
6.6 million newborns being prevented from the disease
[8,42]. Data collected from the sentinel sites in several
countries showed that the prevalence of microfilaraemia
had been reduced by 60% to 100% after 5-6 rounds of
MDA [42], and that Egypt, after 5 rounds of MDA at
high coverage, is likely to join the list of countries that
has successfully eliminated LF [43]. Despite the progress
made, 20 out of 71 endemic countries that require
MDA are still yet to start the control programme.
Schistosomiasis
Schistosomiasis, or bilharzia, caused by the schistosome
trematode, is one of the most debilitating helminthic
diseases among rural populations. There are three major
species that cause tremendous human morbidity, Schis-
tosoma haematobium and Schistosoma mansoni predo-
minantly in Africa, and Schistosoma japonicum in the
Far East. Schistosomiasis can cause a wide range of
symptoms and consequences depending on the species,
the worm burden and the length of time infected [44].
Globally there are over 200 million people infected with
the disease with many more at the risk of being infected,
and the majority are in sub-Saharan Africa [45].
In China, the national control programme for schisto-
somiasis has restricted the disease to very limited areas
with relatively low prevalence via decades of compre-
hensive control effort [46,47]. In Brazil and Egypt, simi-
lar successes in schistosomiasis control have also been
Table 1 Risk factors, comprehensive control measures and endpoint control targets for each of five major neglected
tropical diseases (NTDs)
Disease Major factors for human infection Comprehensive control
measures
Endpoint targets of control
Onchocerciasis Parasites
Black flies (transmitting infective larvae during blood
feeding)
Human activities (near black fly breeding sites)
Treatment with ivermectin
Health education for self-
protection
Case management
Elimination
Lymphatic
filariasis
Parasites
Mosquitoes (transmitting infective larvae during blood
feeding)
Poor sanitation (mosquito breeding sites)
Human behaviour (without self-protection)
Treatment with albendazole plus
ivermectin or diethylcarbamazine
Self-protection (bed net)
Health education for behavioural
change
Hygiene and sanitation
Case management
Elimination as a public health
problem worldwide by the year
2020
Schistosomiasis Parasites
Intermediate host snails in fresh water releasing infective
larvae
Poor hygiene and sanitation
Human behaviour (water contact and defecating/urinating
in/near water)
Treatment with praziquantel
Snail management
Health education for behavioural
change
Hygiene and sanitation
Clean water supply
Hospitalisation of severe cases
Morbidity control
Soil-transmitted
helminthiasis
Parasites
Poor hygiene and sanitation
Human behaviour (passing eggs to the environment in
faeces, barefoot, not washing hands, and so on)
Treatment with albendazole or
mebendazole
Health education for behavioural
change
Hygiene and sanitation
Clean water supply
Morbidity control
Trachoma Bacteria
Poor hygiene and sanitation
Human behaviour (lack of facial washing)
SAFE strategy:
Surgical case management (S)
Treatment with azithromycin (A)
Clean water supply for facial
washing (F)
Hygiene and sanitation in the
environment (E)
Health education for behavioural
change
Elimination as a blinding disease
worldwide by the year 2020
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control strategy recommended by the WHO is to con-
trol morbidity due to schistosomiasis by MDA with pra-
ziquantel, targeting mainly school-age children and
adults at high risk of infection. Preschool children and
infants are also being consid e r e df o ri n c l u s i o ni nt h e
target population [50]. Unlike for other major NTDs
there has been limited drug donation and so praziquan-
tel has had to be purchased, although it is now available
at low cost. In 2002, the Schistosomiasis Control Initia-
tive was established with support from the Bill &
Melinda Gates Foundation, and has since delivered over
40 million treatments in sub-Saharan Africa using prazi-
quantel [51]. The treatment made a significant impact
on infection [52,53] and morbidity [54,55] in the tar-
geted populations. Currently there are 13 countries in
sub-Saharan Africa that are implementing integrated
NTD control programmes in which schistosomiasis con-
trol is an important component, however the majority
of endemic countries are still yet to start such integrated
control programmes.
Soil-transmitted helminthiasis
Soil-transmitted helminthiasis (STH) is caused by a
group of parasitic nematode worms (most importantly,
hookworms, Ascaris lumbricoides and Trichuris tri-
chiura) through ingestion of parasite eggs or contact
with skin-penetrating larvae that are present in the con-
taminated environment. These diseases are by far the
most common NTDs in the developing world [3],
affecting school-age children in particular and causing
anaemia and other forms of malnutrition [18-22,56].
The control strategy is morbidity control through MDA
using albendazole or mebendazole. Generally, control of
STH is integrated into other programmes such as nutri-
tion or school health as a deworming component, and
is often part of schistosomiasis control programmes or
as a collateral benefit from LF control programmes, as
the same drug is used. Addition of mebendazole to vita-
min A supplementation expanded the treatment to chil-
dren of 12-59 months with a high coverage [57].
Children Without Worms (CWW) was established as a
partnership between Johnson & Johnson and the Task
Force for Global Health to leverage the donation of
mebendazole from Johnson & Johnson to advocate for
comprehensive and sustainable control of STH with a
focus exclusively on school-age children http://www.
childrenwithoutworms.org. Despite these efforts, less
t h a n2 0 %o ft h ea t - r i s ks c h o o l -age population receive
deworming treatment worldwide [58]; this is far short of
the World Health Assembly’s target to regularly treat 75%
of school-age children at risk of morbidity due to schisto-
somiasis and STH infections by 2010 [59]. As for schisto-
somiasis control, only a few countries are currently
implementing or about to implement national integrated
NTD control programmes that include STH control.
Trachoma
Trachoma, a recurrent eye infection caused by the bac-
teria, Chlamydia trachomatis, is the leading infectious
(and thus preventable) causeo fb l i n d n e s sw o r l d w i d e .
Repeated infection of the conjunctiva lining the under-
neath of the eyelid leads to scarring and the eventual
turning-in of the eyelid, causing the eyelashes to rub
against the eye itself. This painful condition, called tri-
chiasis, eventually abraded the cornea and results in
irreversible blindness.
Trachoma is endemic in 57 countries, particularly in
sub-Saharan Africa, the Middle East and Asia, with the
highest prevalence rates reported in sub-Saharan Africa
[60]. The disease affects the poorest populations in the
world. It is estimated that there are currently over 40
million people with the infectious form of the disease,
and 8.2 million people that have trichiasis and are thus
at risk of blindness. It is further estimated that over 7
million people have been blinded by trachoma [60].
The WHO, through the Global Alliance for the Elimi-
nation of Blinding Trachoma (GET2020), endorses the
SAFE strategy (for ‘Surgery for trichiasis, Antibiotics to
treat infections, Facial cleaning and Environmental
improvement to reduce transmission’) [61,62] to elimi-
nate this disease as a cause of blindness by the year
2020 [63]. In 1998, the International Trachoma Initiative
(ITI), now part of the Task Force for Global Health, was
established by the Edna McConnell Clark Foundation
and Pfizer, Inc. [64], and has been working with govern-
mental and non-governmental partners to support the
implementation of the SAFE strategy in 18 endemic
countries through the donation of the drug Zithromax
(azithromycin) by Pfizer as the ‘A’ component of the
SAFE strategy. As a result of this donation programme
and the implementation of the other components of the
SAFE strategy, in 2006 Morocco announced the elimina-
tion of trachoma as a public health problem. Several
countries such as Ghana, Iran, Oman, Mexico and Saudi
Arabia have since followed suit.
Trachoma control is currently included in the inte-
grated control of NTDs but primarily for antibiotic dis-
tribution (the ‘A’ component). Funds to support the
other components in the SAFE strategy, particularly sur-
gery for trichiasis, have to be sourced elsewhere.
Recommendations for a sustainable success in the control
of NTDs
Long-term commitment
The increasing commitment by the governmental and
non-governmental donors in funding the control of
NTDs has excited many. In 2006, the US Congress
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for International Development to target the aforemen-
tioned ‘tool-ready’ NTDs. In 2008, President Bush
launched the NTD Initiative with $350 million over 5
years to provide treatment to over 300 million people in
developing countries. In 2009, President Obama
announced a new global health initiative with $63 billion
over 6 years to address a range of global health pro-
blems including NTDs. The US Government has since
steadily increased funding in NTD control over the last
few years, from $15 million per year during 2006-2008,
to $25 million in 2009, and to $65 million for 2010. The
UK government also announced a commitment of £50
million over 5 years towards NTD control and elimina-
tion. In 2009, a $34 million grant was also provided by
the Bill & Melinda Gates Foundation to establish regio-
nal strategies and funding mechanisms and leverage new
investments to control or eliminate NTDs by 2020.
Indeed, with the funding provided, many countries have
now been able to implement their integrated NTD con-
trol programmes.
However, caution must be taken to avoid being over-
optimistic and sending the wrong messages to donors
for achieving the stated goals over a short period of
time. Overoptimism can artificially raise donor expecta-
tions, which may not be met during the funding period.
Experience shows that a successful control programme
needs a long-term effort. It has been decades since
schistosomiasis control programmes started in China in
the 1950 s with a comprehensive control strategy [47]
and in Brazil in the mid 1970 s with (mainly) che-
motherapy [48], yet effort in control is still required and
ongoing. There have been resurgences (or re-
emergences) of schistosomiasis in previously controlled
areas [47,65]. With onchocerciasis, it took 15-17 years
of biannual MDA plus vector control to reduce the pre-
valence to a very low level as in Senegal and Mali [35].
It is therefore important that donors are aware that the
overall objectives in controlling or eliminating NTDs
may not be achieved after one or two rounds of a 5-year
funding cycle using the current strategy, and that long-
term commitment and investment are needed.
A long-term commitment is also required from the
endemic countries. Current integrated control pro-
grammes are almost exclusively funded by external
sources. It is recognised that the governments of ende-
mic countries have to balance resource allocation for
NTD control against a high burden of more dramatic
diseases, and as such they rarely allocate budgets for
implementation activities of NTD control programmes.
However, in-kind contributions have been made as well
as the commitment to integrate NTD activities into
health systems. For long-term sustainable control, the
endemic countries need to progressively take on the
responsibility of such control programmes. This will
also ensure that the residual levels of NTDs will be
manageable within the health system when they cease to
be of public health significance following intensive
large-scale, relatively expensive, and community based
interventions. It is also important for the beneficiary
communities to realise that a long-term commitment is
needed from them.
Partnerships
Successful control of NTDs needs a strong partnership
involving all stakeholders across the various sectors. The
successes of OCP, APOC, GPELF and GET2020 are all
stories of partnerships of donors, the World Health
Organization, pharmaceutical industries, governments of
endemic countries, communities, and non-governmental
developmental organisations (NGDOs). Commitment
from the pharmaceutical industries to continue to
donate the necessary drugs is also vital. Currently, Mec-
tizan for onchocerciasis treatment will be donated by
Merck for as long as is needed and with as much as is
needed [66]. Albendazole for LF will be donated by
GlaxoSmithKline for as long as necessary to eliminate
LF to meet the current target of elimination by 2020
[67]. Pfizer donates Zithromax for trachoma treatment
that is necessary to achieve the goal of the elimination
of blinding trachoma by 2020. Johnson&Johnson also
donates mebendazole for STH treatment. However, the
funds provided by donors to deliver these drugs to the
populations in need are still not enough [68]. Therefore,
in order to better use the limited resources, all the sta-
keholders within a country including donors and
NGDOs, coordinated by governments of endemic coun-
tries, need to work together to identify those priority
areas most in need and to plan and implement the con-
trol activities in a coordinated and harmonised way to
avoid repetition and overlapping in both funding and
e f f o r t .I nt h i sp a r t n e r s h i p ,N G D O sh a v eav e r yi m p o r -
tant role in assisting countries to raise funds and plan
and implement the programmes, as has been demon-
strated in onchocerciasis control [69].
Concerted action
Successful control of these diseases and the alleviation
of the suffering of millions of people from long-term ill-
ness, disfigurement, social stigma and marginalisation,
and decreased productivity require concerted action.
Concerted action is needed from donors. Currently,
the US government, the UK government, the Bill&Me-
linda Gates Foundation and some other private donors
have provided some of the much-needed funds.
Although G8 leaders put NTDs on the global health
agenda and called for sustained action against NTDs, so
far no major funding has come through from other
major donor countries. With the improvement of the
global economic situation, more donors need to fulfil
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cause of NTD control so that efforts can be scaled up to
reach all those people in need [70].
Concerted action is also needed from the endemic
countries. Many of the NTDs spread across borders.
Cross-border transmission of the NTDs is common
because of the movement of populations. Expanding
control efforts into bordering countries will be critical,
as successful NTD control programmes in one country
may be undermined by cross-border traffic from neigh-
bouring countries where there are no NTD control pro-
grammes [68]. The neighbouring countries can also
work together to exchange experience in planning,
implementation, training and advocacy [51,71].
Comprehensive control measures
The current strategy for integrated control of NTDs is
preventive chemotherapy using the available drugs [30]
f o ro n eg r o u po fN T D st h a ts h a r eM D Aa sac o m m o n
strategy. Therefore, the current major funding for the
integrated NTD control programmes focuses almost
exclusively on integrated MDA, ignoring a number of
other components that are critical to the control, miti-
gation and in some cases the elimination of these dis-
eases. For a long-term and sustainable impact, other
measures (for example, clean water supply, hygiene and
sanitation, behavioural changes, and vector manage-
ment) must be addressed. The importance of socioeco-
nomic development in NTD control needs to be
recognised and appropriate collaboration sought when
implementing NTD interventions. While these other
measures will need concerted action from all relevant
sectors and may not be fully addressed within an indivi-
dual programme, for the purpose of morbidity control,
extreme cases (for example, trichiasis, hydrocele, and
elephantiasis) must be cared for and be included in the
current funding. The control programme per se can
actually benefit from such inclusion of case management
as it has been shown that including lymphoedema man-
agement in the control programme can increase the
community compliance with MDA [72]. In the case of
trachoma control, the objective is global elimination of
trachoma as a blinding disease by year 2020 using the
SAFE strategy. In the current major funding, only the
‘A’ component is supported, that is, MDA with Zithro-
max, while the ‘S’, ‘F’ and ‘E’ components are over-
looked. Without addressing the ‘F’ and ‘E’ components,
the disease is guaranteed to return in the long term.
There are currently 8.2 million people worldwide with
trichiasis, the stage of trachoma that leads to irreversible
blindness [60]. If funding for surgery for these cases (the
‘S’ component) is not provided in the major funding, the
main objective of GET2020 will never be achieved.
There is a similar case for LF elimination for which dis-
ability management and prevention is of equal
importance in the programme in order to attain the
elimination goal. Another disease for which other com-
plementary measures should be included is schistoso-
miasis. MDA with praziquantel alone showed excellent
results in reducing prevalence and intensity of infection
in the integrated control programmes [52,53,73], but it
also showed difficulties in reducing infection in heavy
endemic areas with close proximity to major water
bodies [52], as the once a year treatment does not pre-
vent reinfection. Even in areas where prevalence is
reduced to very low levels by consecutive MDA, there is
still a risk of recrudescence of the disease as shown in
China [47,65]. The helminth control programme on
Zanzibar Island is another good example of why com-
prehensive control measures are needed [74,75]. There-
fore, for long-term sustainable control, there should be
other measures including clean water supply, hygiene
and sanitation such as latrine building and use, health
education for behavioural change, and snail manage-
ment if possible.
Implementation through the primary healthcare system and
capacity building
In most developing countries, particularly in the poorest
areas, there is a lack of fully functional infrastructure in
the health service system. If strengthened, this system
can be comprehensive, flexible in adjusting to changing
disease patterns, permanent, and embedded in commu-
nity life [76]. As an integrated NTD control programme
is implemented in a country, it is important to avoid
creating a separate parallel health service system relative
to the existing one, and to avoid undermining the
already under-resourced healthcare systems [77]. In
areas with poor infrastructure and poor resources, a
programme-oriented approach has been effective to
achieve maximum effect in a short period of time in
onchocerciasis control using community-directed inter-
ventions in APOC. However, for a long-term benefit
and sustainable control programme on NTDs, it is vital
to integrate NTD control into the existing primary
healthcare system as routine health service operations
where possible and thus to strengthen the infrastructure
of the primary health system through such control pro-
grammes [76,78,79]. This is exemplified by the success-
ful integration of NTD drug delivery through the
national Child Health Days in Uganda [80,81]. Experi-
ence from the national integrated NTD control pro-
gramme in Sierra Leone showed that implementing the
programme involving the existing health service system
actually helped rebuild and strengthen the system (M
Hodges, personal communication).
The national NTD control programme belongs to the
country and the beneficiary communities that need to
take the ownership and responsibility over the imple-
mentation of the programme. For a successful control
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country capacity to implement such integrated control
programmes. Under the current funding structure, an
international organisation or an NGDO (or a consor-
tium) is required to provide technical assistance and
support in financial management to the national pro-
gramme. It is vital that the government and the commu-
nities, rather than NGDOs, take the lead in planning
and implementation of the programme. With the assis-
tance from NGDOs, the programme can start from a
limited scale to gain experience and build capacity
through training and implementation, and then expand
progressively.
Conclusions
Control of the NTDs has gained momentum in the last
few years. The burden of these diseases on over 2 billion
people in the poorest areas and the importance of con-
trolling these NTDs for a wide range of benefits are
recognised by the international community [70]. While
impressive progress has been made in investment and
control of the diseases, a long-term commitment from
existing donors must be emphasised and funding from
more governmental and non-governmental donors must
be mobilised in order to ensure that the billions of peo-
ple afflicted by the NTDs benefit from such a large-
scale international effort. With increased funding in the
control of NTDs, the NTD control community must
remain objective and maintain focus on maximum
achievement with currently available resources. The cur-
rent level of funding for NTD control has never been
seen before, but it is still not enough to scale up to all
people in all endemic countries, and the duration of
assured funding is not known. The stakeholders must
work in a coordinated and harmonised way to identify
the priority areas and the best delivery approach to use
the current funds to maximum effect. Case management
and other necessary measures should be supported in
the current funding stream in order to achieve the
objectives of these disease controls. For a long-term and
sustainable effort, control of NTDs should also be inte-
grated into the primary healthcare system and
strengthen the needed supporting structures where
required.
Acknowledgements
Helen Keller International’s programmes on the control of neglected tropical
diseases in Africa received financial supports from the United States Agency
for International Development through RTI International, the European
Union, the Conrad N Hilton Foundation, the Lions Clubs International
Foundation, the African Program for Onchocerciasis Control, the Mectizan
Donation Program, the Nippon Foundation, the Government of Taiwan, the
Government of South Korea through Heart to Heart Foundation, the World
Food Program, and other private donors. Views expressed in this paper are
solely those of the authors and not necessarily of the World Health
Organization or the donor agencies.
Author details
1Helen Keller International, Regional Office for Africa, Dakar, Senegal.
2Helen
Keller International, Headquarters, New York, the USA.
3World Health
Organization, Regional Office for Africa, Harare, Zimbabwe.
Authors’ contributions
YZ drafted the manuscript, and all authors contributed to and revised the
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 28 July 2010 Accepted: 29 October 2010
Published: 29 October 2010
References
1. Molyneux DH, Hotez PJ, Fenwick A: “Rapid-impact interventions”: how a
policy of integrated control for Africa’s neglected tropical diseases could
benefit the poor. PLoS Med 2005, 2:e336.
2. Hotez PJ, Molyneux DH, Fenwick A, Ottesen E, Ehrlich Sachs S, Sachs JD:
Incorporating a rapid-impact package for neglected tropical diseases
with programs for HIV/AIDS, tuberculosis, and malaria. PLoS Med 2006, 3:
e102.
3. Hotez PJ, Molyneux DH, Fenwick A, Kumaresan J, Sachs SE, Sachs JD,
Savioli L: Control of neglected tropical diseases. N Engl J Med 2007,
357:1018-1027.
4. Mathew AA, Turner A, Taylor HR: Strategies to control trachoma. Drugs
2009, 69:953-970.
5. Wright HR, Turner A, Taylor HR: Trachoma. Lancet 2008, 371:1945-1954.
6. Stingl P: Onchocerciasis: developments in diagnosis, treatment and
control. Int J Dermatol 2009, 48:393-396.
7. Berger IB, Nnadozie J: Onchocerciasis and other eye problems in
developing countries: a challenge for optometrists. J Am Optom Assoc
1993, 64:699-702.
8. Ottesen EA, Hooper PJ, Bradley M, Biswas G: The global programme to
eliminate lymphatic filariasis: health impact after 8 years. PLoS Negl Trop
Dis 2008, 2:e317.
9. Hepburn NC: Cutaneous leishmaniasis: an overview. J Postgrad Med 2003,
49:50-54.
10. Barrett R: Self-mortification and the stigma of leprosy in northern India.
Med Anthropol Q 2005, 19:216-230.
11. Hartzell JD, Zapor M, Peng S, Straight T: Leprosy: a case series and review.
South Med J 2004, 97:1252-1256.
12. Pszolla N, Sarkar MR, Strecker W, Kern P, Kinzl L, Meyers WM, Portaels F:
Buruli ulcer: a systemic disease. Clin Infect Dis 2003, 37:e78-82.
13. Fevre EM, Wissmann BV, Welburn SC, Lutumba P: The burden of human
african trypanosomiasis. PLoS Negl Trop Dis 2008, 2:e333.
14. Kennedy PG: The continuing problem of human African trypanosomiasis
(sleeping sickness). Ann Neurol 2008, 64:116-126.
15. Sanchez-Sancho F, Campillo NE, Paez JA: Chagas disease: progress and
new perspectives. Curr Med Chem 2010, 17:423-52.
16. Ong A, Sandar M, Chen MI, Sin LY: Fatal dengue hemorrhagic fever in
adults during a dengue epidemic in Singapore. Int J Infect Dis 2007,
11:263-267.
17. Kheir MM, Eltoum IA, Saad AM, Ali MM, Baraka OZ, Homeida MM: Mortality
due to Schistosomiasis mansoni: a field study in Sudan. Am J Trop Med
Hyg 1999, 60:307-310.
18. Hotez PJ, Molyneux DH: Tropical anemia: one of Africa’s great killers and
a rationale for linking malaria and neglected tropical disease control to
achieve a common goal. PLoS Negl Trop Dis 2008, 2:e270.
19. Brooker S, Hotez PJ, Bundy DA: Hookworm-related anaemia among
pregnant women: a systematic review. PLoS Negl Trop Dis 2008, 2:e291.
20. Stephenson LS: Helminth parasites, a major factor in malnutrition. World
Health Forum 1994, 15:169-172.
21. Stephenson LS, Latham MC, Ottesen EA: Malnutrition and parasitic
helminth infections. Parasitology 2000, 121(Suppl):S23-38.
22. Bates I, McKew S, Sarkinfada F: Anaemia: a useful indicator of neglected
disease burden and control. PLoS Med 2007, 4:e231.
23. Friedman JF, Kanzaria HK, McGarvey ST: Human schistosomiasis and
anemia: the relationship and potential mechanisms. Trends Parasitol 2005,
21:386-392.
Zhang et al. BMC Medicine 2010, 8:67
http://www.biomedcentral.com/1741-7015/8/67
Page 7 of 924. Hotez PJ, Kamath A: Neglected tropical diseases in sub-saharan Africa:
review of their prevalence, distribution, and disease burden. PLoS Negl
Trop Dis 2009, 3:e412.
25. Raso G, Luginbuhl A, Adjoua CA, Tian-Bi NT, Silue KD, Matthys B,
Vounatsou P, Wang Y, Dumas ME, Holmes E, Singer BH, Tanner M,
N’goran EK, Utzinger J: Multiple parasite infections and their relationship
to self-reported morbidity in a community of rural Cote d’Ivoire. Int J
Epidemiol 2004, 33:1092-1102.
26. McKenzie FE: Polyparasitism. Int J Epidemiol 2005, 34:221-222, author reply
222-223.
27. Conteh L, Engels T, Molyneux DH: Socioeconomic aspects of neglected
tropical diseases. Lancet 2010, 375:239-247.
28. Ehrenberg JP, Ault SK: Neglected diseases of neglected populations:
thinking to reshape the determinants of health in Latin America and the
Caribbean. BMC Public Health 2005, 5:119.
29. Brady MA, Hooper PJ, Ottesen EA: Projected benefits from integrating
NTD programs in sub-Saharan Africa. Trends Parasitol 2006, 22:285-291.
30. World Health Organization: Preventive Chemotherapy in Human Helminthiasis
Geneva, Switzerland: World Health Organization; 2006.
31. African Programme for Onchocerciasis Control: Report of the sixth
meeting of national task forces, October 2009. Wkly Epidemiol Rec 2010,
85:23-28.
32. Sauerbrey M: The Onchocerciasis Elimination Program for the Americas
(OEPA). Ann Trop Med Parasitol 2008, 102(Suppl 1):25-29.
33. Hougard JM, Poudiougo P, Zerbo G, Meyer R, Guillet P, Agoua H, Seketeli A,
Akpoboua A, Sowah S, Samba EM, et al: Control of onchocerciasis vectors
in West Africa: description of the logistics adapted for a large-scale
public health program [in French]. Sante 1994, 4:389-398.
34. Amazigo U: The African Programme for Onchocerciasis Control (APOC).
Ann Trop Med Parasitol 2008, 102(Suppl 1):19-22.
35. Diawara L, Traore MO, Badji A, Bissan Y, Doumbia K, Goita SF, Konate L,
Mounkoro K, Sarr MD, Seck AF, Toé L, Tourée S, Remme JH: Feasibility of
onchocerciasis elimination with ivermectin treatment in endemic foci in
Africa: first evidence from studies in Mali and Senegal. PLoS Negl Trop Dis
2009, 3:e497.
36. Ottesen EA, Duke BO, Karam M, Behbehani K: Strategies and tools for the
control/elimination of lymphatic filariasis. Bull World Health Organ 1997,
75:491-503.
37. Ottesen EA: Lymphatic filariasis: treatment, control and elimination. Adv
Parasitol 2006, 61:395-441.
38. Sun DJ: Global significance of the elimination of lymphatic filariasis in
China [in Chinese]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing
Za Zhi 2005, 23(5 Suppl):329-331.
39. World Health Organization: Global programme to eliminate lymphatic
filariasis. Wkly Epidemiol Rec 2008, 83:333-341.
40. Cheun HI, Lee JS, Cho SH, Kong Y, Kim TS: Elimination of lymphatic
filariasis in the Republic of Korea: an epidemiological survey of formerly
endemic areas, 2002-2006. Trop Med Int Health 2009, 14:445-449.
41. Cheun HI, Kong Y, Cho SH, Lee JS, Chai JY, Lee JK, Kim TS: Successful
control of lymphatic filariasis in the Republic of Korea. Korean J Parasitol
2009, 47:323-335.
42. World Health Organization: Global programme to eliminate lymphatic
filariasis. Wkly Epidemiol Rec 2009, 84:437-444.
43. Ramzy RM, El Setouhy M, Helmy H, Ahmed ES, Abd Elaziz KM, Farid HA,
Shannon WD, Weil GJ: Effect of yearly mass drug administration with
diethylcarbamazine and albendazole on bancroftian filariasis in Egypt: a
comprehensive assessment. Lancet 2006, 367:992-999.
44. Fenwick A, Zhang Y: Schistosomiasis. In Infectious Diseases.. 3 edition.
Edited by: Cohen J, Opal SM, Powderly WG. Amsterdam, The Netherlands:
Elsevier; 2010.
45. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J: Schistosomiasis and
water resources development: systematic review, meta-analysis, and
estimates of people at risk. Lancet Infect Dis 2006, 6:411-425.
46. Xianyi C, Liying W, Jiming C, Xiaonong Z, Jiang Z, Jiagang G, Xiaohua W,
Engels D, Minggang C: Schistosomiasis control in China: the impact of a
10-year World Bank Loan Project (1992-2001). Bull World Health Organ
2005, 83:43-48.
47. Wang L, Utzinger J, Zhou XN: Schistosomiasis control: experiences and
lessons from China. Lancet 2008, 372:1793-1795.
48. Katz N: Schistosomiasis control in Brazil. Mem Inst Oswaldo Cruz 1998,
93(Suppl 1):33-35.
49. Webbe G, el Hak S: Progress in the control of schistosomiasis in Egypt
1985-1988. Trans R Soc Trop Med Hyg 1990, 84:394-400.
50. Stothard JR, Gabrielli AF: Schistosomiasis in African infants and preschool
children: to treat or not to treat? Trends Parasitol 2007, 23:83-86.
51. Fenwick A, Webster JP, Bosque-Oliva E, Blair L, Fleming FM, Zhang Y,
Garba A, Stothard JR, Gabrielli AF, Clements AC, Kabatereine NB, Toure S,
Dembele R, Nyandindi U, Mwansa J, Koukounari A: The Schistosomiasis
Control Initiative (SCI): rationale, development and implementation from
2002-2008. Parasitology 2009, 136:1719-1730.
52. Zhang Y, Koukounari A, Kabatereine N, Fleming F, Kazibwe F, Tukahebwa E,
Stothard JR, Webster JP, Fenwick A: Parasitological impact of 2-year
preventive chemotherapy on schistosomiasis and soil-transmitted
helminthiasis in Uganda. BMC Med 2007, 5:27.
53. Toure S, Zhang Y, Bosque-Oliva E, Ky C, Ouedraogo A, Koukounari A,
Gabrielli AF, Bertrand S, Webster JP, Fenwick A: Two-year impact of single
praziquantel treatment on infection in the national control programme
on schistosomiasis in Burkina Faso. Bull World Health Organ 2008,
86:780-787, A.
54. Kabatereine NB, Brooker S, Koukounari A, Kazibwe F, Tukahebwa EM,
Fleming FM, Zhang Y, Webster JP, Stothard JR, Fenwick A: Impact of a
national helminth control programme on infection and morbidity in
Ugandan schoolchildren. Bull World Health Organ 2007, 85:91-99.
55. Koukounari A, Gabrielli AF, Toure S, Bosque-Oliva E, Zhang Y, Sellin B,
Donnelly CA, Fenwick A, Webster JP: Schistosoma haematobium infection
and morbidity before and after large-scale administration of
praziquantel in Burkina Faso. J Infect Dis 2007, 196:659-669.
56. King CH, Dickman K, Tisch DJ: Reassessment of the cost of chronic
helmintic infection: a meta-analysis of disability-related outcomes in
endemic schistosomiasis. Lancet 2005, 365:1561-1569.
57. World Health Organization: How to Add Deworming to Vitamin A Distribution
Geneva, Switzerland: World Health Organization; 2004.
58. CWW: A closer look at soil-transmitted helminth (STH) infections. [http://
www.childrenwithoutworms.org/].
59. WHO: Deworming for health and development. [http://whqlibdoc.who.int/
hq/2005/who_cds_cpe_pvc_2005.14.pdf].
60. Burton MJ, Mabey DC: The global burden of trachoma: a review. PLoS
Negl Trop Dis 2009, 3:e460.
61. West SK: Blinding trachoma: prevention with the safe strategy. Am J Trop
Med Hyg 2003, 69(5 Suppl):18-23.
62. Chami Y, Hammou J, Mahjour J: Lessons from the moroccan national
trachoma control programme. Community Eye Health 2004, 17:59.
63. Mariotti SP, Pararajasegaram R, Resnikoff S: Trachoma: looking forward to
Global Elimination of Trachoma by 2020 (GET 2020). Am J Trop Med Hyg
2003, 69(5 Suppl):33-35.
64. Kumaresan JA, Mecaskey JW: The global elimination of blinding
trachoma: progress and promise. Am J Trop Med Hyg 2003, 69(5
Suppl):24-28.
65. Liang S, Yang C, Zhong B, Qiu D: Re-emerging schistosomiasis in hilly and
mountainous areas of Sichuan, China. Bull World Health Organ 2006,
84:139-144.
66. Merck: Merck MECTIZAN Donation Program. [http://www.merck.com/
corporate-responsibility/access/access-developing-emerging/mectizan-
donation-riverblindness/approach.html].
67. GlaxoSmithKline: Our commitment on LF. [http://www.gsk.com/filariasis/
commitment.htm].
68. Fenwick A, Zhang Y, Stoever K: Control of the neglected tropical diseases
in sub-Saharan Africa: the unmet needs. International Health 2009, 1:61-70.
69. Haddad D: The NGDO co-ordination group for onchocerciasis control.
Ann Trop Med Parasitol 2008, 102(Suppl 1):35-38.
70. Molyneux DH: Neglected tropical diseases - beyond the tipping point?
Lancet 2010, 375:3-4.
71. Garba A, Toure S, Dembele R, Bosque-Oliva E, Fenwick A: Implementation
of national schistosomiasis control programmes in West Africa. Trends
Parasitol 2006, 22:322-326.
72. Cantey PT, Rout J, Rao G, Williamson J, Fox LM: Increasing compliance
with mass drug administration programs for lymphatic filariasis in India
through education and lymphedema management programs. PLoS Negl
Trop Dis 2010, 4:e728.
73. Tohon ZB, Mainassara HB, Garba A, Mahamane AE, Bosque-Oliva E,
Ibrahim ML, Duchemin JB, Chanteau S, Boisier P: Controlling
schistosomiasis: significant decrease of anaemia prevalence one year
Zhang et al. BMC Medicine 2010, 8:67
http://www.biomedcentral.com/1741-7015/8/67
Page 8 of 9after a single dose of praziquantel in Nigerian schoolchildren. PLoS Negl
Trop Dis 2008, 2:e241.
74. Knopp S, Mohammed KA, Rollinson D, Stothard JR, Khamis IS, Utzinger J,
Marti H: Changing patterns of soil-transmitted helminthiases in Zanzibar
in the context of national helminth control programs. Am J Trop Med
Hyg 2009, 81:1071-1078.
75. Stothard JR, French MD, Khamis IS, Basanez MG, Rollinson D: The
epidemiology and control of urinary schistosomiasis and soil-transmitted
helminthiasis in schoolchildren on Unguja Island, Zanzibar. Trans R Soc
Trop Med Hyg 2009, 103:1031-1044.
76. Gyapong JO, Gyapong M, Yellu N, Anakwah K, Amofah G, Bockarie M,
Adjei S: Integration of control of neglected tropical diseases into health-
care systems: challenges and opportunities. Lancet 2010, 375:160-165.
77. McCoy D, Chopra M, Loewenson R, Aitken JM, Ngulube T, Muula A, Ray S,
Kureyi T, Ijumba P, Rowson M: Expanding access to antiretroviral therapy
in sub-saharan Africa: avoiding the pitfalls and dangers, capitalizing on
the opportunities. Am J Public Health 2005, 95:18-22.
78. Victora CG, Hanson K, Bryce J, Vaughan JP: Achieving universal coverage
with health interventions. Lancet 2004, 364:1541-1548.
79. Hopkins AD: Challenges for the integration of mass drug administrations
against multiple ‘neglected tropical diseases’. Ann Trop Med Parasitol
2009, 103(Suppl 1):S23-31.
80. Kabatereine NB, Fleming FM, Nyandindi U, Mwanza JC, Blair L: The control
of schistosomiasis and soil-transmitted helminths in East Africa. Trends
Parasitol 2006, 22:332-339.
81. Kolaczinski JH, Kabatereine NB, Onapa AW, Ndyomugyenyi R, Kakembo AS,
Brooker S: Neglected tropical diseases in Uganda: the prospect and
challenge of integrated control. Trends Parasitol 2007, 23:485-493.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1741-7015/8/67/prepub
doi:10.1186/1741-7015-8-67
Cite this article as: Zhang et al.: Control of neglected tropical diseases
needs a long-term commitment. BMC Medicine 2010 8:67.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Zhang et al. BMC Medicine 2010, 8:67
http://www.biomedcentral.com/1741-7015/8/67
Page 9 of 9